Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial
Open Access
- 1 February 2021
- journal article
- letter
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 84 (2) , 495-497
Abstract
No abstract availableFunding Information
- Regeneron Pharmaceuticals
- Sanofi
This publication has 5 references indexed in Scilit:
- Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part IIJournal of the European Academy of Dermatology and Venereology, 2018
- Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part IJournal of the European Academy of Dermatology and Venereology, 2018
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017
- ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patientsJournal of the European Academy of Dermatology and Venereology, 2016
- Guidelines of care for the management of atopic dermatitisJournal of the American Academy of Dermatology, 2014